Market capitalization | $216.99m |
Enterprise Value | $185.96m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.44 |
P/S ratio (TTM) P/S ratio | 0.51 |
P/B ratio (TTM) P/B ratio | 0.79 |
Revenue growth (TTM) Revenue growth | 1.59% |
Revenue (TTM) Revenue | $426.10m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
17 Analysts have issued a Nevro forecast:
17 Analysts have issued a Nevro forecast:
Dec '23 | |
Current assets | 531 531 |
Fixed assets | 105 105 |
Total Assets | 636 636 |
Dec '23 | |
Equity | 293 293 |
Debt capital | 343 343 |
Total Capital | 636 636 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Kevin Thornal |
Employees | 1,215 |
Founded | 2006 |
Website | www.nevro.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.